8.40 +0.10 (1.20%)
After hours: 6:26PM EDT
|Bid||8.22 x 1100|
|Ask||8.40 x 2200|
|Day's Range||8.10 - 8.41|
|52 Week Range||3.92 - 21.71|
|Beta (3Y Monthly)||0.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 5, 2019 - Aug 9, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.75|
Shares of Karyopharm Therapeutics reversed an early pop Friday after gaining FDA approval for a drug called Xpovio as a multiple myeloma treatment. Shares of biotech DBV also soared higher.
The FDA's decision to approve Xpovio was based on the overall response rate of 25.3% in the 83-patient subgroup of the Phase 2b STORM trial, White said in a Friday note. H.C. Wainwright estimates the sales potential in the penta-refractory setting to be $5.5 million in 2019, rising to $123.8 million in 2026.
The drug developer’s stock leapt in the middle of this week after the Food and Drug Administration approved Karyopharm’s drug Xpovio for use treating multiple myeloma patients for whom other therapies had failed.
The following is a roundup of the top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs July 3.) • Abbott Laboratories (NYSE: ABT ) • Apellis ...
Wednesday, the stock of Karyopharm Therapeutics Inc. advanced more than 35% in trading. The trigger for the rally was U.S. Food and Drug Administration (FDA) approval of its compound Xpovio, also known as selinexor, for the treatment of penta-refractory multiple myeloma. It was an unexpected victory for Karyopharm and its shareholders considering a recent 8-5 vote by an FDA advisory committee recommending that approval of Xpovio be delayed until additional Phase 3 data was disclosed later this year.
Yesterday, Karyopharm Therapeutics announced that it had received FDA approval for the first and only nuclear export inhibitor, XPOVIO.
Karyopharm (KPTI) gets accelerated FDA approval for oral Xpovio in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma.
Shares of Karyopharm Therapeutics Inc. soared 36% in very active trade Wednesday, enough to pace the Nasdaq exchange's gainers, prior to a trading hold for news. The drug maker focused on cancer treatments disclosed after the close that the U.S. Food and Drug Administration has approved oral XPOVIO in combination with dexamethasone for the treatment of relapsed or refactory multiple myeloma in adult patients. Karyopharm expects XPOVIO to become commercially available in the U.S. on or before July 10, 2019. "With today's accelerated approval of XPOVIO by the FDA, patients with heavily pretreated multiple myeloma will now have a new therapeutic option to treat their disease," said Chief Scientific Officer Sharon Shacham. The stock can resume trading at 1:35 p.m. Eastern. The stock has still shed 5.1% year to date, while the S&P 500 has gained 19.5%.
The U.S. Food and Drug Administration on Wednesday approved Karyopharm Therapeutics Inc's treatment for multiple myeloma, a type of blood cancer. "Sadly, often over time, patients can exhaust all available treatments and still see their disease progress," said Richard Pazdur, director of the FDA's Oncology Center of Excellence. Karyopharm said it expects Xpovio to become commercially available in the United States by July 10.
Karyopharm Therapeutics Inc. (KPTI), an oncology-focused pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved oral XPOVIOTM (selinexor), a nuclear export inhibitor, in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate.
Around 32,000 Americans are diagnosed with multiple myeloma each year, according to the American Cancer Society. Karyopharm's drug will be used in patients who have not responded to at least four prior therapies.
Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 55,500 shares of Karyopharm’s common stock to eight newly-hired employees, with a grant date of June 28, 2019. The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with NASDAQ Listing Rule 5635(c)(4). Each of the stock options has an exercise price of $5.99 per share, the closing price of Karyopharm’s common stock on June 28, 2019. Each stock option vests over four years, with 25% of the original number of shares underlying the stock option vesting on the one-year anniversary of the applicable employee’s employment commencement date and an additional 1/48th of the shares vesting monthly thereafter, subject to the employee’s continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates.
Investors need to pay close attention to Karyopharm Therapeutics (KPTI) stock based on the movements in the options market lately.
A market surge in the first quarter, spurred by easing global macroeconomic concerns and Powell's pivot ended up having a positive impact on the markets and many hedge funds as a result. The stocks of smaller companies which were especially hard hit during the fourth quarter slightly outperformed the market during the first quarter. Unfortunately, […]
Biotech companies once again dominate the BBJ’s annual list of fastest-growing public companies in Massachusetts. Paratek Pharmaceuticals Inc., headquartered in Boston, ranks first on the list this year with revenue growth between 2016 and 2018 of 58,924 percent.
− Once Weekly Oral Selinexor in Combination with Kyprolis® and Low Dose Dexamethasone Demonstrates 78% ORR in Patients with Heavily Pretreated, Kyprolis-Naïve Multiple Myeloma –.
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
NEWTON, Mass., May 28, 2019 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that the Company’s management team will.